IFAPP TODAY

The Global Newsletter on Pharmaceutical Medicine

THIS ISSUE

In Memoriam Professor Dr. Gerfried Nell 1941 – 2021

It is with great sadness that GPMed says goodbye to Professor Gerfried Nell.

After graduation from medical school in 1965, Prof. Nell was trained as a pharmacologist at the University of Vienna and the University of Saarland in Homburg/Saar. Following several management positions in the pharmaceutical industry in Indianapolis/USA and Konstanz, Germany, he was Medical Director at Novartis Austria until his retirement.

IFAPP TODAY
The Global Newsletter on Pharmaceutical Medicine

Prof. Nell was the second President of GPMed (Society for Pharmaceutical Medicine) from 2002 to 2004. Under his presidency, the GPMed went more international. The cooperation in pharmaceutical medicine was intensified, in particular within the DACH region (including Germany and Switzerland). Prof. Nell also worked closely with the international umbrella organisation of pharmaceutical physicians, IFAPP (International Federation of Associations of Pharmaceutical Physicians & Pharmaceutical Medicine). Even after his presidency, Prof. Nell was active in GPMed as an IFAPP delegate.

From 2008-2011, Prof. Nell was elected President of IFAPP. Finally, in 2019, Prof. Nell was honoured by IFAPP as a "Hero in Pharmaceutical Medicine" for his work and contribution to Pharmaceutical Medicine.

Prof. Nell passed away after a long, serious illness on 6 September 2021.

His work and commitment to GPMed and Pharmaceutical Medicine in Austria and internationally will remain unforgotten.

PD Dr. Johannes Pleiner-Duxneuner, Medical Director Roche Austria and President of the Austrian national member association of pharmaceutical physicians GPMed (Gesellschaft für Pharmazeutische Medizin e.V.)

A Fulfilling Decision: Crossing the Bridge for the Patients

Up to now I am still amazed and often asked by friends, relatives and colleagues in healthcare: “Why did you cross the bridge and decided to be on the dark side?" Well, I just laugh at them and ask them: “Why do you say so? Isn’t it that you should be the one making your own light and help guide others from whatever side of the world you are in?” That was the perception that I initially noticed when they knew that I left to join the pharmaceutical industry in 2009.

I finished my medical school at the University of the Philippines College of Medicine and had residency training at the University of the Philippines – Philippine General Hospital Department of Family and Community Medicine. A university that I well love because it has instilled in me the values of being patient-centric and service-oriented. I was trained in a government institution and developed that passion to look beyond the illness and see the patient in its holistic view. That advocacy to be patient-focused and bring the discussion with the patient in the equation has guided me in my journey in the pharma and healthcare industry. I was initially a manager at Lifestyle Medicine/Employee Healthcare Service at the Asian Hospital and Medical Center. I left a legacy in the institution when I was tasked to design an evidence-based medical wellness programme. I was also tasked to make a time and motion study and meet the challenge to turn around results with interpretation of exams within 4 hours for patients availing of evidence-based wellness packages.

IFAPP TODAY
The Global Newsletter on Pharmaceutical Medicine

Even for employee healthcare service we played a role together with my fellow family physicians as gate keeper and economist in ensuring that we judiciously utilised the funds of the institution for the employees which we can proudly say was a success because we were able to extend benefits to their family members.

I initially entered the pharmaceutical industry when I joined Abbott as a Medical Advisor handling various therapy areas and Affiliate Safety Officer. It was my role as an Affiliate Safety Officer that made me passionate discussing the importance of Pharmacovigilance with the healthcare industry in coordination with the Philippine FDA. When I joined GSK, I was awarded the Global Platinum Award on a Patient Safety Advocacy Programme. I embraced the principles of Pharmacovigilance and shed that light to my commercial partners for them to appreciate the importance of Drug Safety reporting. That communication of drug features and benefits should be balanced with safety communication because at the end of the day it is the patient that matters. I further extended that passion by learning on how we can safeguard sensitive and personal information by acting as a compliance officer and attend trainings on the Data Privacy Act when I was in the Abbott-AbbVie Product Division. Medical marketing within bounds of compliance was also an advocacy which I learned in my communication with commercial colleagues ensuring that the patient is given a voice during discussions backed-up by scientific data. I am now with Pfizer as Associate Medical Director in Product Safety Surveillance and Research, an area that I am very passionate, and I have vowed to embrace with my life - Pharmacovigilance.

Prior to the pandemic, I had the opportunity to enrol in the Diploma Course in Pharmaceutical Medicine and Management at the Ateneo de Manila Graduate School of School of Business, Center for Continuing Education, which helped broaden my horizon. I also had the privilege to earn a seat at the Board of Directors of the Philippine College of Pharmaceutical Medicine.

My passion and focus to aim for greater heights are fuelled by my background in media when I had a chance to work as Science Researcher in ABS-CBN for an educational show – “Sine-eskwela”. I got to contribute articles to DIWA Publishing house Salaguinto and Bato-balani which spreads knowledge on science, ethics, and moral values amongst graduate school students. I am also a trained private pilot at Airpsan and Omni-aviation in Clark Field Pampanga. During my free time I spend time for singing karaoke, Chinese painting, fishing, and cooking for my family.

So, what is life at the other side of the bridge? It is fulfilling because I was able to use my learnings from the other side of the river and crossed it to the next side with still the patients as a focus of all my activities. So now as a member of the IFAPP Communication Working Group I have another golden chance to advocate for the patients!

Cheers!

Rodelio Camesa Bito, MD, Associate Medical Director, PSSR - Pfizer Inc. (Philippines),
Member of the IFAPP Communication Working Group

IFAPP TODAY
The Global Newsletter on Pharmaceutical Medicine

Philippine College of Pharmaceutical Medicine

The Philippine College of Pharmaceutical Medicine (PCPM) is an affiliate society of the Philippine Medical Association, composed of licensed healthcare professionals who work in the pharmaceutical industry. Bound by a shared mission of championing medical governance and driving high ethical standards in the practice of pharmaceutical medicine, this group of healthcare professionals strives to continuously learn and work with all stakeholders, both in private and government sectors to uphold ethics and excellence in healthcare.

VISION

Envision a professional pharmaceutical industry that is consistently committed to the highest ethical values and practices of medical governance that is anchored on the passion to promote the health and well-being of citizens in the Philippines.

MISSION

LEADERS FOR HEALTH that champion governance, promote medical ethics, and enforce ethical practices in the pharmaceutical industry of the Philippines.

The Philippine College of Pharmaceutical Medicine plays a key role as an advocate by promoting professional relationships with key stakeholders, academic research institutes, government, medical societies, and pharmaceutical companies. It champions a Code of Medical Governance among its members. It is committed to consistently apply the highest standards in medical research and ethical practices in Pharmaceutical Medicine. It upholds the highest ethical standards in the promotion of health products. Moreover, it endeavours to sustain professional interest in pharmaceutical medicine through specialty training and continuing education in the field of pharmaceutical medicine.

The following are core activities of the organisation:

- Professional Certification
  - o Diploma Course in Pharmaceutical Medicine and Management
- Continuing Education Programme
  - o PCPM Annual Convention
  - o Quarterly Continuing Education Programme
- Mentoring Programme
- Health Advocacy and Other Special Programmes

IFAPP TODAY

The Global Newsletter on Pharmaceutical Medicine

The organisation was initially conceptualised on 15th August 1969 and led by its first president, Dr. Francisco Pascual (1970-71). The organisation was formed initially by medical directors of various pharmaceutical industry leaders, thus it was initially coined as Association of Medical Directors of the Philippine Pharmaceutical Industries (AMDPPI). The organisation held partnerships with the Philippine Medical Association in 1972 and with the Drug Association of the Philippines and the Department of Health in 1978.

The organisation underwent 5 decades of transformation. It was in 1991 that the organisation was named as Philippine College of Pharmaceutical Medicine. It has now more than 170 active members. Organisation membership has also evolved and now includes Medical Affairs advisors, managers and Medical Scientific Liaison officers as members. It is currently led by Dr. Jonas Policarpio, President, and Dr. Ronald Subida as Past President and 11 board directors.

Dr. Jonas Policaprio

Dr. Ronald Subida

The Philippine College of Pharmaceutical Medicine in collaboration with the Ateneo de Manila School of Business–Center for Continuing Education, has formed its flagship programme Diploma Course in Pharmaceutical Medicine and Management (DPMM). The Memorandum of Understanding between the two parties represented by PCPM President Dra. Sonia Bongala and Dean Rodolfo Ang respectively was formalised on 1st October 2015. The programme is in line with the Philippine Food and Drug Administration (FDA) requirement under DOH-AO No. 2014-0040 that all Medical Directors or those with an equivalent role title, thereof, of all drug establishments operating in the country, should have a Diploma in Pharmaceutical Medicine or passed the examinations given by the Specialty Board of Pharmaceutical Medicine.

IFAPP TODAY
The Global Newsletter on Pharmaceutical Medicine

The course covers 7 domains (modules) that is aligned with the curriculum of the International Federation of Association of Pharmaceutical Physicians and Pharmaceutical Medicine (IFAPP) and runs for 20 session days or the equivalent of 160 hours. This is followed by a certifying examination administered by the PCPM Board that will form the basis of the registration approval of a Medical Director with the Philippine FDA.

At present the Diploma Course in Pharmaceutical Medicine and Management (DPMM) has 75 graduates. PCPM is running its first online DPMM course programme (5th batch) this year with 25 enrolees in this time of pandemic.

Rodelio Camesa Bito, MD
Associate Medical Director
PSSR - Pfizer Inc. (Philippines)
Member of the IFAPP Communication Working Group

SBMF Educational Initiative on Pharmaceutical Medicine and Vaccines for Parliamentarians in Brazil

In October 2021 a course specially designed to educate policy makers about drug development with a special focus on vaccines will start in Brazil. The course is called INTERCONNECT. INTERCONNECT was conceived by INTERFARMA and built by SBMF (Sociedade Brasileira de Medicina Farmacêutica).

INTERFARMA is the association that represents more than 50 multinational pharmaceutical companies in Brazil, i.e., companies that invest in research and development of innovative therapies, vaccines and treatments for rare diseases, oncology, chronic and genetic diseases.

INTERCONNECT will have 5 modules on specific topics ranging from drug and vaccine development, regulatory and health safety aspects, clinical research, conditions for the promotion of innovation to discussions on pricing and patient access to therapies by SUS (Sistem Único de Saúde, public health system) and the private health system.

The pharmaceutical industry made important efforts to address the challenges of the pandemic in this period. Many projects arose in the legislature with the theme focused on public health, stimulating research and innovation, vaccines and patient care. This demanded a lot of dedication from advisors, legislative consultants and parliamentarians to understand this very relevant and challenging topic.

INTERFARMA, as part of its mission and purpose, has to be a credible source of information for opinion makers and decision makers. The National Congress, undoubtedly, is one of the most important instances in the construction (or alteration) of health policies, with direct impact on the pharmaceutical industry, research and Brazilian patients.

IFAPP TODAY
The Global Newsletter on Pharmaceutical Medicine

Thus, this series of workshops should serve as support to the teams and parliamentarians in the National Congress on key issues for the development of the pharmaceutical industry in the country, as well as greater access to patients.

The SBMF objective in this task is to foster debate on technical aspects related to Pharmaceutical Medicine, including research with medicines, vaccines, medical equipment and diagnostics and health products in general; scientific support to the medical professionals and the population for the correct use of these products; registration; technical-scientific development; safety for the use of medicines and other medical and/or pharmacological aspects within Pharmaceutical Medicine.

SBMF built INTERCONNECT inviting distinguished specialists - physicians, researchers, public servants, and representatives of international bodies who accepted to participate as speakers in this series of events.

It is a great satisfaction for SBMF to be able to contribute to an initiative like this, bringing renowned specialists with the aim of providing technical data and science-based information to legislative consultants and parliamentarians.

Hélio Osmo, MD, MBA, GFMD*
Presidente SBMF (Sociedade Brasileira de Medicina Farmacêutica)
*Global Fellow in Medicines Development of IFAPP (International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine)

In 2021 SBMF proudly celebrates the 50th anniversary of its foundation.

Drug Development in Times of Corona – Lessons Learned

Report from a 16 September 2021 GPMed (Austria) Webinar

PD Dr. Johannes Pleiner-Duxneuner, President of GPMed, and Assoc. Prof. Dr. Markus Zeitlinger, Vice President of GPMed, welcomed the participants and introduced the speakers.

IFAPP TODAY
The Global Newsletter on Pharmaceutical Medicine

Marouan Zarrouk PhD, Project Manager VACCELERATE from the University Hospital of Cologne, presented a platform launched by the European Commission for research into vaccines against SARS-CoV-2 infections. As the largest study network for phase 2 and 3 COVID-19 vaccination studies, partners in 23 countries are involved, and a total of 467 study centres are covered. This enables research into the details of approved vaccines (there are 2 projects underway for boosting in people who have already been primed), as well as accelerated testing of new vaccines. The latter has been massively hampered by the increasing vaccination coverage of the population for subsequent vaccines.

Prof. Andrea Laslop, Head of the Scientific Office at AGES, acting as the link between the European Medicines Agency (EMA) and the national Austrian competent authority AGES PharmMed, explained the tasks of the EMA in the exceptional situation of a pandemic, emphasising how important it was to bundle resources and involve all EU countries, especially against the background of many small studies and compassionate use programmes in the individual countries. As another problem area, she highlighted the inspections of clinical trials, which often had to be carried out as "remote inspections" due to the pandemic, with varying degrees of success. To accompany the pandemic on the EMA side until its end, the COVID-19 pandemic task force was set up, with experts from various EMA committees and working groups as well as external participants such as patient representatives. In the last part of her presentation, Prof. Laslop explained on the one hand the rapid scientific advice, which leads in a very flexible way to advice from the EMA in a maximum of 20 days and has already been given in 116 of the 129 scientific advice procedures on the topic of COVID-19. On the other hand, she went into more detail on the rolling review, which can be carried out very quickly through a continuous assessment of data, whereby it is assumed that the quality of the assessment must be given as usual, as well as the conditional approval of the EMA and, above all, the difference to the emergency approval of the FDA, which is only valid temporarily and is not an approval in the actual sense.

Christoph Jandl PhD, Head of Medical Affairs Austria and UK at Valneva, presented the work of the vaccine developer Valneva, which emerged in Austria from the company Intercell and still has a large local presence. He outlined the general challenges of pandemic vaccine development, which must be much faster than conventional vaccines, where processes such as production and global "vaccination" run in parallel, and where there is centralised distribution. In addition, there are COVID-19 specific aspects, which meant almost completely new territory, where completely new paths had to be taken and often framework conditions changed several times (virus mutations, study designs, export bans, supply bottlenecks, rapid set-up, and regulatory approval of new production sites, etc.). Therefore, the importance of national and international cooperation was also emphasised here. Finally, Mr. Jandl went into more detail about the Valneva COVID-19 vaccine VLA2001, where the read-out of the phase 3 data is expected in October.

Dr. Dejan Baltic, Medical Director Amgen Austria and member of the GPMed Board

IFAPP TODAY

The Global Newsletter on Pharmaceutical Medicine

The Swiss Clinical Trial Organisation: A Cooperation Platform for Patient-Oriented Clinical Research in Switzerland

The Swiss Clinical Trial Organisation (SCTO) is a research infrastructure committed to high quality, patient-oriented clinical research in Switzerland. An independent, not-for-profit organisation funded by Switzerland's State Secretariat for Education, Research and Innovation (SERI) and the Swiss National Science Foundation (SNSF), its mission is to advance academic clinical research in Switzerland as a nationwide cooperation platform and international networking partner.

The SCTO's primary objective is to **catalyse valuable, innovative, and visible clinical research in Switzerland** that results in better therapies for society and thus contributes to public health. As an umbrella organisation, the SCTO's mission is to **make a substantial contribution to developing an optimal framework for academic clinical research.** This includes enabling research in all disease areas and for all patient populations to be performed according to the highest standards and in an efficient, successful, and internationally competitive manner.



Facilitating Academic Clinical Research and Ensuring Continuing Education

The SCTO represents and coordinates a network of professional research infrastructures and topic-based platforms for clinical research in Switzerland.

At the operational level, the SCTO's Clinical Trial Unit (CTU) Network offers services for the implementation of trials. The network is made up of seven local CTUs, which are predominantly located in university hospitals, and plays a key role in facilitating academic clinical research. Acting as an academic partner, the network offers comprehensive support and represents Switzerland's largest provider of training and services for any kind of clinical research. In doing this, the SCTO contributes to the high-quality training of future clinical researchers.

IFAPP TODAY
The Global Newsletter on Pharmaceutical Medicine

A Nationally Harmonised Study Culture

In close collaboration with its CTUs and the Swiss Group for Clinical Cancer Research (SAKK), the SCTO developed an overall concept for quality assurance for its CTU Network in its Guidelines for Good Operational Practice, with the main objective being to improve patient safety and the integrity of data in clinical research. These guidelines describe the jointly defined quality standards for operational practice in the CTUs. They provide guidance on implementing a process-oriented quality management system at the CTUs' operational level and include guidelines for data management and risk-based monitoring.





SCTO Platforms: Expertise and High-Quality Tools for Academic Clinical Research Professionals

To further streamline clinical research infrastructures, in 2017 the SCTO established a network of interconnected, topic-based platforms that serve as pools of expertise on key areas in clinical research: auditing, data management, education, monitoring, project management, regulatory affairs, safety, and statistics and methodology. Each CTU coordinates one of the SCTO platforms. Here too, the SCTO liaises with and between these individual platforms as well as with external partners and supports them in their activities.

SCTO's platforms have developed a wide range of practical tools and resources – including templates, guidance documents, online training, and statistics packages – that support members of the national and international academic research communities in their day-to-day work. **Visit and browse the platforms' dedicated Tools & Resources website: www.sctoplatforms.ch.**

Fostering Patient and Public Involvement in Academic Clinical Research

The success of clinical research in Switzerland depends not only on the goodwill of patients as participants in clinical trials but also increasingly on their active involvement. The SCTO supports the dialogue between researchers and patients and advocates for patient and public involvement (PPI) in academic clinical research. One of the SCTO's most important strategic goals for the 2021–2024 funding period is to establish a centralised coordination hub and point of contact for all PPI stakeholders. This PPI hub's activities will span organisations and diseases.

IFAPP TODAY
The Global Newsletter on Pharmaceutical Medicine

As a first step, the SCTO conducted, together with its partner organisations, a survey to identify and characterise local and national PPI initiatives in the academic environment. The results of the survey will be presented as a mapping of all identified PPI initiatives/projects and provide a solid basis for determining the status quo in Switzerland. The SCTO's PPI team compiled a fact sheet explaining the overall concept of PPI, its benefits and challenges, and how it can be incorporated in clinical trials. The SCTO published an additional guide for researchers on how they can address PPI in clinical trials. This guide also helps researchers to identify opportunities within their clinical trial that can inspire effective and meaningful PPI when starting to plan a project and when applying for potential funding. Both documents were prepared in close collaboration with the Swiss National Science Foundation (SNSF) and are available on the SCTO's website: SCTO's contributions to PPI {https://www.scto.ch/en/publications/fact-sheets].

National and International Networking as the Key to Success

To advocate for favourable framework conditions, the SCTO maintains regular contact with federal authorities and institutions and builds bridges between academia, industry, authorities, and the public. Furthermore, the SCTO acts as the Swiss national hub within the European Clinical Research Infrastructure Network (ECRIN), connecting the CTU Network with other European networks of clinical research centres and clinical trial units. Through its partnership with the Swiss Research Network of Clinical Pediatric Hubs (SwissPedNet), the SCTO also supports the development of new or optimised medical treatments and diagnostic procedures for children and adolescents. And finally, the SCTO is the contact point for industry, cooperative groups, and other third parties.

If you have a question or are interested in learning more about the SCTO, please contact the Communications and Stakeholder Engagement team at **info@scto.ch or visit our website www.scto.ch/en**.

Tamara Kohler, Patient and Public Involvement (PPI) Project Manager; **Jadranka Knesevic**, Communications Manager; **Cordula Landgraf, Pharm.D.**, Communications and Stakeholder Engagement Director, Swiss Clinical Trial Organisation, Chair IFAPP External Affairs Working Group; IFAPP Board of Officers

IFAPP TODAY
The Global Newsletter on Pharmaceutical Medicine

Reorientating FPM for the Future

COVID-19 has dominated the news since the latter part of 2019. Like many organisations, the UK-based Faculty of Pharmaceutical Medicine (FPM) had to pivot to deliver its operations remotely once the government introduced lockdown. FPM had already begun the major introduction of a new website and introduction of on-line examinations which are remotely proctored. These initiation steps enabled FPM to pivot quickly into a period of innovation as the barriers to change were lowered to ensure that FPM thrived during this unprecedented time. So, what have been some of those changes?

Communication and Advocacy

During 2020 FPM's focus was on informing and guiding the public and policy makers on the science around the SARS-CoV-2 virus, and some of the ethics and practicalities of dealing with the resulting pandemic. We have also been learning from and supporting FPM members in their work, whether they are directly involved in developing therapeutics and vaccines for COVID-19, adapting their usual operations to cope with the pandemic, or seeking to get involved with the NHS vaccination programme.

One casualty of the COVID-19 pandemic has been the unprecedented disruption to clinical trial programmes, potentially impacting on the development of new medicines and treatments for patients and the public. One such disruption has been seen in the difficulties in enrolling patients onto trials, highlighting the need to identify practical measures that will provide future resilience. In collaboration with the ABPI and the MHRA, FPM carried out a survey to identify the innovations and adaptions that have been undertaken to maintain clinical trial programmes during the COVID-19 crisis. The findings led to FPM holding a workshop to discuss the key findings of

- Embedding resilience into the delivery of clinical trials through the adoption of technology as well as changing practice and process
- Addressing global health challenges through harnessing the power of science, innovation, and collaboration to combat future global health threats – pandemics, aging populations, climate change
- Providing education and training to enhance the knowledge and skills of health professionals who will be needed to respond to future pandemics.

FPM Blogs

FPM collaborated with experts to produce a series of blogs that covered different aspects of the COVID-19 crisis, including:

- Does SARS-CoV-2 cause a vascular disease? By FPM President Professor Tim Higenbottam (Does SARS-CoV-2 cause a vascular disease? - FPM)
- A review of vaccine development by Dr Penny Ward (COVID-19/SARS-CoV-2 Pandemic - FPM)
- The ethics of conducting clinical trials in search of treatments for COVID-19 by Dr Susan Tansey (The ethics of conducting clinical trials in the search for treatments and vaccines against COVID-19 - FPM)
- What you need to know about COVID-19 testing by Dr Bob Holland (What you need to know about COVID-19 testing - FPM)

IFAPP TODAY
The Global Newsletter on Pharmaceutical Medicine

New Member Events

FPM established its virtual Journal Club in May 2020, and it has been a huge success with the members. Those hosting sessions reflect the diversity of the FPM membership, and it has provided another avenue to facilitate member engagement with FPM. Papers debated at Journal Club in 2020 included:

- Oral immunotherapy for peanut allergy
- Factors associated with COVID-19 related hospital deaths
- Highly precise risk prediction model for new-onset hypertension using artificial intelligence techniques
- Dexamethasone in hospitalised patients with COVID-19

We have also initiated 'Fireside Chats' which are small, intimate virtual gatherings, to listen to an FPM member's thoughts on a burning issue and their experiences, tales and learnings from a career in Pharmaceutical Medicine.

FPM Global

FPM's attention is also turning to developing its new strategy for 2023-25, which will be focused on sustainable growth in a volatile, uncertain, complex, and ambiguous world. To support and guide this, a new committee, FPM Global, has been formed with members from diverse locations such as the USA, South Africa, Nigeria, Pakistan, Switzerland, and Hong Kong, as well as the UK. It is hoped that FPM Global will facilitate international collaboration to promote and grow awareness of the Pharmaceutical Medicine Specialty which is only recognised as a medical specialty in the UK, Republic of Ireland, and Switzerland. The main purpose of FPM Global is to

- Raise awareness of Pharmaceutical Medicine as the profession representing the clinical science for the development of medicines and medical devices
- Support the global recognition of Pharmaceutical Medicine as a medical specialty
- Propose new training and assessment opportunities that meets local needs
- Contribute to the setting of world-wide standards in Pharmaceutical Medicine
- Help grow the membership of FPM

2021 and Beyond

FPM is now entering the next stage of its evolution. In May 2021 the revised curriculum for the Pharmaceutical Medicine Specialty Training programme (PMST) was approved by the General Medical Council and this is now being rolled out to new trainees. FPM is investing in its education and training function, which will strengthen FPM's role in setting the standards in Pharmaceutical Medicine. A plan to develop a bespoke programme of masterclasses as well as skills-based training which will be launched in 2022 is underway. FPM continues to invest in its provision to hold its examinations online with remote invigilation which allows candidates to sit their exams at home or at work. Indeed, there has been an increase in the number of overseas

IFAPP TODAY
The Global Newsletter on Pharmaceutical Medicine

candidates who are registering to sit the exams in their home nation. We are hoping also to build on the success of the undergraduate curriculum in medicines development, which has now run as part of the medical programme at Brighton and Sussex Medical School for several years. We hope to expand this to other settings.

Through the development of multi-delivery educational channels that complement the traditional face to face delivery, FPM will be able to offer a diverse range of educational programmes. Members will have access to a learning management system so that they can undertake asynchronous learning that fits in with their professional and personal commitments.

Finally, in October 2021, a new Board of Trustees will be instituted, Prof Tim Higenbottam, the current President, will step down, and the newly elected President, Dr Flic Gabbay, will carry on the work to modernise FPM so that it continues to increase its influence through the promotion of Pharmaceutical Medicine as an important medical specialty which has a pivotal role to play in combatting future health pandemics.

Prof Tim Higgenbottam

Dr Flic Gabbay

Dr Marcia Philbin

Dr Marcia Philbin, CChem FRSC MAPM
Chief Executive, Faculty of Pharmaceutical Medicine

Faculty of **Pharmaceutical Medicine**

Advancing the science and practice of pharmaceutical medicine for the benefit of the public

IFAPP TODAY
The Global Newsletter on Pharmaceutical Medicine

Second Announcement of Next Free IFAPP Webinar on Regional COVID-19 Updates

COVID-19 in Sub-Saharan Africa

IFAPP is honoured to announce the next free webinar on regional COVID-19 issues, in collaboration with Fundisa African Academy of Medicines Development. This webinar will be presented on 18 November 2021, at 2.00 pm CET. Scientific experts from the African region will address the management of the pandemic from their perspectives as follows:

Prof Rhoda Wanyenze, Dean of Makerere University School of Public Health (MakSPH), Kampala, Uganda; "COVID-19 - Experiences from Uganda, Democratic Republic of Congo, Senegal, and Nigeria"

Pr**of Charles Wiysonge**, Director of Cochrane South Africa, Medical Research Council, Cape Town, South Africa: "Vaccine Policy, Usage and Vaccine Hesitancy in SA"

Prof Elmien du Plessis, Associate Professor, Faculty of Law, Northwest University, Potchefstroom, South Africa: "Legal Responses to the Pandemic in South Africa, including Human Rights Considerations"

The moderators will be Dr med Bernd Rosenkranz, FFPM, Prof. em. (Stellenbosch University), President, Fundisa African Academy of Medicines Development, Visiting Scientist, Institute for Clinical Pharmacology and Toxicology, Charité Universitätsmedizin, Berlin, Germany, and Prof Wolfgang Preiser, Head: Division of Medical Virology, Faculty of Medicine and Health Sciences, Stellenbosch University and National Health Laboratory Service (NHLS), Tygerberg, South Africa.

Registration is free, please click here.

IFAPP TODAY

The Global Newsletter on Pharmaceutical Medicine

Our last IFAPP TODAY of the year will be released by the end of November.

THE FLAG

IFAPP secretariat - Leidsestraatweg 41d - 3443 BP Woerden - The Netherlands
Chamber of Commerce 30224375 – VAT number NL817747321B02
Phone: (+31) 6 2291 1039 – e-mail: secretariat@ifapp.org – website: www.ifapp.org

IFAPP Communication Working Group
Ghazaleh Gouya-Lechner (Chair), Varvara Baroutsou, Rodelio Bito, Brigitte Franke-Bray, Kotone Matsuyama, Helio Osmo, Johanna Schenk, Peter Stilting.

IFAPP is the International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine.

Follow us on: